LORATADINE TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
02-05-2013
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
LORATADINE
Tilgjengelig fra:
MYLAN PHARMACEUTICALS ULC
ATC-kode:
R06AX13
INN (International Name):
LORATADINE
Dosering :
10MG
Legemiddelform:
TABLET
Sammensetning:
LORATADINE 10MG
Administreringsrute:
ORAL
Enheter i pakken:
12/18/24/30
Resept typen:
OTC
Terapeutisk område:
SECOND GENERATION ANTIHISTAMINES
Produkt oppsummering:
Active ingredient group (AIG) number: 0120416001; AHFS:
Autorisasjon status:
CANCELLED PRE MARKET
Autorisasjon dato:
2016-11-02
Preparatomtale
PRODUCT MONOGRAPH
LORATADINE
Loratadine Tablets
10 mg
USP
Histamine H
1
receptor antagonist
Mylan Pharmaceutical ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Revision Date: April 23, 2013
Control Number: 160783
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY
PRODUCT
INFORMATION
................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS
AND
PRECAUTIONS
.........................................................................................
4
ADVERSE
REACTIONS
...........................................................................................................
5
DRUG
INTERACTIONS
...........................................................................................................
7
DOSAGE
AND
ADMINISTRATION
.......................................................................................
8
OVERDOSAGE
.........................................................................................................................
8
ACTION
AND
CLINICAL
PHARMACOLOGY
......................................................................
9
STORAGE
AND
STABILITY
.................................................................................................
11
SPECIAL
HANDLING
INSTRUCTIONS
...............................................................................
11
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ..................................................... 11
PART II: SCIENTIFIC INFORMATION
...............................................................................
12
PHARMACEUTICAL
INFORMATION
.................................................................................
12
CLINICAL
TRIALS
............................................................
Les hele dokumentet
